Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram

被引:193
作者
Liechti, ME [1 ]
Baumann, C [1 ]
Gamma, A [1 ]
Vollenweider, FX [1 ]
机构
[1] Univ Zurich, Hosp Psychiat, Dept Res, CH-8029 Zurich, Switzerland
关键词
3,4-methylenedioxymethamphetamine; MDMA; Ecstasy; serotonin; citalopram; selective serotonin reuptake inhibitors; psychological effects;
D O I
10.1016/S0893-133X(99)00148-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy" is a recreational drug that has been shown to release serotonin (5-HT) and dopamine (DA) in animals. The effect of MDMA on 5-HT release can be blocked by 5-HT uptake inhibitors such as citalopram, suggesting that MDMA interacts with the 5-HT uptake site. It is unknown whether this mechanism is also responsible for the psychological effects of MDMA in humans. We investigated the effect of citalopram pretreatment (40 mg iv on the psychological effects of MDMA (1.5 mg/kg po) in a double-blind placebo-controlled psychometric study in 16 healthy human volunteers. MDMA produced an emotional state with heightened mood, increased self-confidence and extroversion, moderate derealization, and an intensification of sensory perception. Most of these effects were markedly reduced by citalopram. This finding suggests that the psychological effects of MDMA are mediated via action at the 5-HT uptake site to increase 5-HT release through the carrier, as expected from animal studies. (C) 2000 American College of Neuropsychopharmacology.
引用
收藏
页码:513 / 521
页数:9
相关论文
共 50 条
  • [41] STEREOCHEMICAL EFFECTS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND RELATED AMPHETAMINE DERIVATIVES ON INHIBITION OF UPTAKE OF [H-3] MONOAMINES INTO SYNAPTOSOMES FROM DIFFERENT REGIONS OF RAT-BRAIN
    STEELE, TD
    NICHOLS, DE
    YIM, GKW
    [J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (14) : 2297 - 2303
  • [42] THE DEMETHYLENATION OF METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY) BY DEBRISOQUINE HYDROXYLASE (CYP2D6)
    TUCKER, GT
    LENNARD, MS
    ELLIS, SW
    WOODS, HF
    CHO, AK
    LIN, LY
    HIRATSUKA, A
    SCHMITZ, DA
    CHU, TYY
    [J]. BIOCHEMICAL PHARMACOLOGY, 1994, 47 (07) : 1151 - 1156
  • [43] Vollenweider FX, 1999, NEUROPSYCHOPHARMACOL, V21, P598
  • [44] Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naive healthy volunteers
    Vollenweider, FX
    Gamma, AG
    Liechti, M
    Huber, T
    [J]. NEUROPSYCHOPHARMACOLOGY, 1998, 19 (04) : 241 - 251
  • [45] Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans
    Vollenweider, FX
    Remensberger, S
    Hell, D
    Geyer, MA
    [J]. PSYCHOPHARMACOLOGY, 1999, 143 (04) : 365 - 372
  • [46] Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
    Vollenweider, FX
    Vollenweider-Scherpenhuyzen, MFI
    Bäbler, A
    Vogel, H
    Hell, D
    [J]. NEUROREPORT, 1998, 9 (17) : 3897 - 3902
  • [47] The effects of methylenedioxymethamphetamine (MDMA, ''Ecstasy'') on monoaminergic neurotransmission in the central nervous system
    White, SR
    Obradovic, T
    Imel, KM
    Wheaton, MJ
    [J]. PROGRESS IN NEUROBIOLOGY, 1996, 49 (05) : 455 - 479
  • [48] THE ACUTE EFFECTS OF METHYLENEDIOXYMETHAMPHETAMINE ON DOPAMINE RELEASE IN THE AWAKE-BEHAVING RAT
    YAMAMOTO, BK
    SPANOS, LJ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 148 (02) : 195 - 203
  • [49] YAMAMOTO BK, 1995, J PHARMACOL EXP THER, V273, P1063
  • [50] [No title captured]